Kimal Rajapakshe

Keywords colorectal cancer metastasis BRAF immunotherapy targeted therapy PD-1 evRNA biomarker clinical trial complement pathway MAPK Introduction A BRAFV600E mutation, present in approximately 8%–10% of all colorectal cancers (CRCs),1,2 is a poor prognostic biomarker for patients with metastatic CRC.3,4,5 Relative to patients with BRAFwild-type CRC, patients with BRAFV600E CRC are more likely to have a right-sided primary tumor location,6,7 advanced age at presentation,5,8 and a poor...

Keywords Mice, Animals, NF-E2-Related Factor 2, Genome-Wide Association Study, Neoplasms, Protein Isoforms, Epidermis Abstract The p53 family member TP63 encodes two sets of N-terminal isoforms, TAp63 and ΔNp63 isoforms. They each regulate diverse biological functions in epidermal morphogenesis and in cancer.

Ewing Sarcoma (EwS) is the second most common malignant bone tumor in adolescents and young adults. The single-most powerful predictor of outcome in EwS is presence of metastatic burden at the time of diagnosis. Patients with metastatic Ewing Sarcoma have an abysmal 5-year survival rate of 10–25%, which has not changed over the past 30–40 years. Thus, unraveling underlying mechanisms of EwS metastasis are imperative for developing effective therapeutic measures.